Gary Ellis Biography and Net Worth

EVP of Medtronic


Gary L. Ellis is an Independent Director of the Company. He was previously Chief Financial Officer and Senior Vice President of Medtronic plc. Mr. Ellis also serves as an independent director of The Toro Company (where he serves as lead director, serves as the chair of the finance committee and serves on the audit committee) and Inspire Medical Systems, Inc. (where he serves as the chair of the nominating committee). He is a Certified Public Accountant. Mr. Ellis brings significant financial leadership experience and expertise to the Board and provides oversight regarding capital structure, financial condition and policies, long-range financial objectives, financing requirements and arrangements, capital budgets and expenditures, risk-management, and strategic planning matters. Additionally, Mr. Ellis contributes his international experience managing worldwide financial operations and analyzing financial implications of merger and acquisition transactions, as well as aligning business strategies and financial decisions.

What is Gary Lee Ellis' net worth?

The estimated net worth of Gary Lee Ellis is at least $2.68 million as of March 15th, 2024. Mr. Ellis owns 33,051 shares of Medtronic stock worth more than $2,678,123 as of December 21st. This net worth evaluation does not reflect any other investments that Mr. Ellis may own. Learn More about Gary Lee Ellis' net worth.

How do I contact Gary Lee Ellis?

The corporate mailing address for Mr. Ellis and other Medtronic executives is 20 ON HATCH LOWER HATCH STREET, DUBLIN L2, D02. Medtronic can also be reached via phone at (531) 438-1700 and via email at [email protected]. Learn More on Gary Lee Ellis' contact information.

Has Gary Lee Ellis been buying or selling shares of Medtronic?

Gary Lee Ellis has not been actively trading shares of Medtronic within the last three months. Most recently, Gary Lee Ellis sold 35,495 shares of the business's stock in a transaction on Wednesday, July 13th. The shares were sold at an average price of $88.64, for a transaction totalling $3,146,276.80. Learn More on Gary Lee Ellis' trading history.

Who are Medtronic's active insiders?

Medtronic's insider roster includes Richard Anderson (Director), Michael Coyle (EVP), Gary Ellis (EVP), Hooman Hakami (EVP), Bryan Hanson (EVP), Omar Ishrak (Chairman), Richard Kuntz (SVP), Bradley Lerman (SVP), John Liddicoat (EVP), Michael Marinaro (EVP), Geoffrey Martha (Chairman of the Board & CEO), Karen Parkhill (CFO), Sean Salmon (EVP), Gregory Smith (EVP), Carol Surface (SVP), Rob Ten Hoedt (EVP), Brett Wall (EVP), Brett Wall (EVP), and Robert White (EVP). Learn More on Medtronic's active insiders.

Are insiders buying or selling shares of Medtronic?

During the last year, insiders at the medical technology company sold shares 3 times. They sold a total of 50,662 shares worth more than $4,285,162.92. The most recent insider tranaction occured on June, 7th when CEO Geoffrey Martha sold 19,113 shares worth more than $1,601,096.01. Insiders at Medtronic own 0.2% of the company. Learn More about insider trades at Medtronic.

Information on this page was last updated on 6/7/2024.

Gary Lee Ellis Insider Trading History at Medtronic

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/13/2016Sell35,495$88.64$3,146,276.80View SEC Filing Icon  
3/25/2015Sell43,183$77.81$3,360,069.23View SEC Filing Icon  
4/1/2014Sell4,246$61.48$261,044.08174,955View SEC Filing Icon  
7/11/2013Sell32,602$53.62$1,748,119.24View SEC Filing Icon  
See Full Table

Gary Lee Ellis Buying and Selling Activity at Medtronic

This chart shows Gary Lee Ellis's buying and selling at Medtronic by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Medtronic Company Overview

Medtronic logo
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Read More

Today's Range

Now: $81.03
Low: $79.80
High: $81.26

50 Day Range

MA: $86.90
Low: $79.99
High: $92.27

2 Week Range

Now: $81.03
Low: $75.96
High: $92.68

Volume

10,706,827 shs

Average Volume

6,272,357 shs

Market Capitalization

$103.90 billion

P/E Ratio

24.78

Dividend Yield

3.44%

Beta

0.82